Opendata, web and dolomites


Commercialization of TREG cells sorting and proliferation in vitro for the production of vaccines for the treatment of type 1 diabetes.

Total Cost €


EC-Contrib. €






Project "TREGS4DM1" data sheet

The following table provides information about the project.


Organization address
address: UL TRZY LIPY 3
city: GDANSK
postcode: 80 172
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Poland [PL]
 Project website
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2016
 Duration (year-month-day) from 2016-07-01   to  2016-12-31


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    POLTREG SPOLKA AKCYJNA PL (GDANSK) coordinator 50˙000.00


 Project objective

The applicant aims at delivering economically sustainable and innovative cell therapy dedicated to the treatment of DM1 with the use of TREGs vaccine. The TREG therapy, covers almost all aspects listed in the call, i.e. cell identification, sorting, culture, multiplication (all 4 steps covered in patent), banking, transport, delivery (running clinical trial) and strict quality control. The project’s objective is to increase the commercial success of the therapy while making it economically effective to the payer (state, local government, national health funds/insurance). The project’s outcome will be an innovative model for treatment of highly devastating disease even with the possibility of preventing highly undesirable side effects for a patient and on a macro-scale for the economy, society and pension scheme. However, in scaling-up, the Company has to identify regulatory pathways to abide even when the technology is out of scope of current regulatory landscape. New therapy means also identification of new business models. Reaching market authorization will be determined on the basis of acceptance of currently carried out academic clinical trials and any further clinical trials ordered by the EMA. Elaboration of feasibility study will allow PolTREG to prepare the necessary strategy for this regulatory requirements.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TREGS4DM1" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TREGS4DM1" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

LEGACy (2019)

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Read More  

HAP2 (2020)

Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired Pneumonia

Read More